SI21403A - Farmacevtska oblika z alendronsko kislino, njenimi solmi ali estri ter postopek za njeno pripravo - Google Patents

Farmacevtska oblika z alendronsko kislino, njenimi solmi ali estri ter postopek za njeno pripravo Download PDF

Info

Publication number: SI21403A
Authority: SI; Slovenia
Prior art keywords: pharmaceutically acceptable; pharmaceutical; form according; pharmaceutical form; group
Prior art date: 2003-02-27

Application number

SI200300052A

Other languages

English (en)

Slovenian (sl)

Inventor

Miha Toma� Jakli�

Vlasta Humar

Debeljak Helena �uklje

Judita �irca

Milojka Mohar

Original Assignee

LEK farmacevtska dru�ba d.d.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-02-27

Filing date

2003-02-27

Publication date

2004-08-31

2003-02-27 Application filed by LEK farmacevtska dru�ba d.d. filed Critical LEK farmacevtska dru�ba d.d.

2003-02-27 Priority to SI200300052A priority Critical patent/SI21403A/sl

2004-02-26 Priority to EP04714997A priority patent/EP1599191B1/de

2004-02-26 Priority to PL377706A priority patent/PL377706A1/pl

2004-02-26 Priority to EA200501221A priority patent/EA009333B1/ru

2004-02-26 Priority to CA2517372A priority patent/CA2517372C/en

2004-02-26 Priority to PCT/SI2004/000011 priority patent/WO2004075828A2/en

2004-02-26 Priority to AT04714997T priority patent/ATE464884T1/de

2004-02-26 Priority to DE602004026689T priority patent/DE602004026689D1/de

2004-08-31 Publication of SI21403A publication Critical patent/SI21403A/sl

Links

OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 title claims abstract description 49
229960004343 alendronic acid Drugs 0.000 title claims abstract description 41
150000003839 salts Chemical class 0.000 title claims abstract description 28
150000002148 esters Chemical class 0.000 title claims abstract description 25
238000002360 preparation method Methods 0.000 title claims abstract description 25
238000000034 method Methods 0.000 title claims abstract description 22
239000000203 mixture Substances 0.000 claims description 47
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 42
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 40
229920000168 Microcrystalline cellulose Polymers 0.000 claims description 27
235000019813 microcrystalline cellulose Nutrition 0.000 claims description 27
239000008108 microcrystalline cellulose Substances 0.000 claims description 27
229940016286 microcrystalline cellulose Drugs 0.000 claims description 27
239000000945 filler Substances 0.000 claims description 25
239000013543 active substance Substances 0.000 claims description 24
239000008194 pharmaceutical composition Substances 0.000 claims description 23
238000000576 coating method Methods 0.000 claims description 21
239000007888 film coating Substances 0.000 claims description 21
238000009501 film coating Methods 0.000 claims description 21
239000000377 silicon dioxide Substances 0.000 claims description 21
235000019359 magnesium stearate Nutrition 0.000 claims description 20
239000011248 coating agent Substances 0.000 claims description 18
239000000314 lubricant Substances 0.000 claims description 17
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 16
239000003826 tablet Substances 0.000 claims description 16
229920002785 Croscarmellose sodium Polymers 0.000 claims description 14
229960001681 croscarmellose sodium Drugs 0.000 claims description 14
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 14
239000000546 pharmaceutical excipient Substances 0.000 claims description 14
239000008187 granular material Substances 0.000 claims description 11
239000011734 sodium Substances 0.000 claims description 11
229910052708 sodium Inorganic materials 0.000 claims description 11
235000010418 carrageenan Nutrition 0.000 claims description 10
239000000679 carrageenan Substances 0.000 claims description 10
229920001525 carrageenan Polymers 0.000 claims description 10
229940113118 carrageenan Drugs 0.000 claims description 10
239000007884 disintegrant Substances 0.000 claims description 10
239000006185 dispersion Substances 0.000 claims description 10
239000000454 talc Substances 0.000 claims description 10
229910052623 talc Inorganic materials 0.000 claims description 10
229940033134 talc Drugs 0.000 claims description 10
235000012222 talc Nutrition 0.000 claims description 10
UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 10
239000007941 film coated tablet Substances 0.000 claims description 9
GUBGYTABKSRVRQ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 claims description 8
229920002472 Starch Polymers 0.000 claims description 8
235000019698 starch Nutrition 0.000 claims description 8
239000008107 starch Substances 0.000 claims description 8
235000021355 Stearic acid Nutrition 0.000 claims description 7
-1 alendronic acid trihydrate Chemical class 0.000 claims description 7
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 7
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 7
229920001223 polyethylene glycol Polymers 0.000 claims description 7
239000008117 stearic acid Substances 0.000 claims description 7
239000004480 active ingredient Substances 0.000 claims description 6
CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 claims description 6
229940063655 aluminum stearate Drugs 0.000 claims description 6
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims description 6
235000013539 calcium stearate Nutrition 0.000 claims description 6
239000008116 calcium stearate Substances 0.000 claims description 6
239000001768 carboxy methyl cellulose Substances 0.000 claims description 6
239000003086 colorant Substances 0.000 claims description 6
MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims description 6
IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 6
239000004014 plasticizer Substances 0.000 claims description 6
239000001267 polyvinylpyrrolidone Substances 0.000 claims description 6
229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 6
235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 6
229940045902 sodium stearyl fumarate Drugs 0.000 claims description 6
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 5
229930195725 Mannitol Natural products 0.000 claims description 5
FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 5
239000003623 enhancer Substances 0.000 claims description 5
239000000594 mannitol Substances 0.000 claims description 5
235000010355 mannitol Nutrition 0.000 claims description 5
229920000642 polymer Polymers 0.000 claims description 5
239000004094 surface-active agent Substances 0.000 claims description 5
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 4
229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 4
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 4
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 4
229920000881 Modified starch Polymers 0.000 claims description 4
239000002202 Polyethylene glycol Substances 0.000 claims description 4
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 4
239000001506 calcium phosphate Substances 0.000 claims description 4
235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 4
239000008112 carboxymethyl-cellulose Substances 0.000 claims description 4
239000001913 cellulose Substances 0.000 claims description 4
235000019700 dicalcium phosphate Nutrition 0.000 claims description 4
235000019333 sodium laurylsulphate Nutrition 0.000 claims description 4
235000010356 sorbitol Nutrition 0.000 claims description 4
239000000600 sorbitol Substances 0.000 claims description 4
238000005550 wet granulation Methods 0.000 claims description 4
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 3
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 3
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
235000021314 Palmitic acid Nutrition 0.000 claims description 3
229930182558 Sterol Natural products 0.000 claims description 3
239000011575 calcium Substances 0.000 claims description 3
229910052791 calcium Inorganic materials 0.000 claims description 3
229910000389 calcium phosphate Inorganic materials 0.000 claims description 3
235000011010 calcium phosphates Nutrition 0.000 claims description 3
229960000541 cetyl alcohol Drugs 0.000 claims description 3
238000007908 dry granulation Methods 0.000 claims description 3
230000002708 enhancing effect Effects 0.000 claims description 3
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims description 3
239000008172 hydrogenated vegetable oil Substances 0.000 claims description 3
239000008101 lactose Substances 0.000 claims description 3
WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims description 3
229920003124 powdered cellulose Polymers 0.000 claims description 3
235000019814 powdered cellulose Nutrition 0.000 claims description 3
235000010413 sodium alginate Nutrition 0.000 claims description 3
239000000661 sodium alginate Substances 0.000 claims description 3
229940005550 sodium alginate Drugs 0.000 claims description 3
150000003432 sterols Chemical class 0.000 claims description 3
235000003702 sterols Nutrition 0.000 claims description 3
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 3
XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 claims description 3
208000001132 Osteoporosis Diseases 0.000 claims description 2
210000000988 bone and bone Anatomy 0.000 claims description 2
230000004097 bone metabolism Effects 0.000 claims description 2
230000003913 calcium metabolism Effects 0.000 claims description 2
238000007907 direct compression Methods 0.000 claims description 2
239000006186 oral dosage form Substances 0.000 claims description 2
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 2
229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims 6
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 3
239000001064 degrader Substances 0.000 claims 3
238000002156 mixing Methods 0.000 claims 3
229920002230 Pectic acid Polymers 0.000 claims 2
LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 claims 2
239000010318 polygalacturonic acid Substances 0.000 claims 2
230000002265 prevention Effects 0.000 claims 2
239000000758 substrate Substances 0.000 claims 2
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical class [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims 1
235000010443 alginic acid Nutrition 0.000 claims 1
239000000783 alginic acid Substances 0.000 claims 1
229920000615 alginic acid Polymers 0.000 claims 1
229960001126 alginic acid Drugs 0.000 claims 1
150000004781 alginic acids Chemical class 0.000 claims 1
239000010408 film Substances 0.000 claims 1
238000000227 grinding Methods 0.000 claims 1
210000002784 stomach Anatomy 0.000 description 19
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
229940062527 alendronate Drugs 0.000 description 16
210000003238 esophagus Anatomy 0.000 description 12
DCSBSVSZJRSITC-UHFFFAOYSA-M alendronate sodium trihydrate Chemical compound O.O.O.[Na+].NCCCC(O)(P(O)(O)=O)P(O)([O-])=O DCSBSVSZJRSITC-UHFFFAOYSA-M 0.000 description 10
230000006378 damage Effects 0.000 description 9
230000007794 irritation Effects 0.000 description 9
210000001035 gastrointestinal tract Anatomy 0.000 description 8
229940122361 Bisphosphonate Drugs 0.000 description 7
238000010521 absorption reaction Methods 0.000 description 7
150000004663 bisphosphonates Chemical class 0.000 description 7
238000001816 cooling Methods 0.000 description 6
238000004090 dissolution Methods 0.000 description 6
239000002552 dosage form Substances 0.000 description 5
241000206575 Chondrus crispus Species 0.000 description 4
230000000694 effects Effects 0.000 description 4
239000002932 luster Substances 0.000 description 4
210000000214 mouth Anatomy 0.000 description 4
239000002245 particle Substances 0.000 description 4
238000012216 screening Methods 0.000 description 4
230000009747 swallowing Effects 0.000 description 4
MCWQUGNJOSKXRB-UHFFFAOYSA-N (4-amino-1-hydroxy-1-phosphonobutyl)phosphonic acid;trihydrate Chemical compound O.O.O.NCCCC(O)(P(O)(O)=O)P(O)(O)=O MCWQUGNJOSKXRB-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
239000002253 acid Substances 0.000 description 3
235000003599 food sweetener Nutrition 0.000 description 3
229960001855 mannitol Drugs 0.000 description 3
210000004400 mucous membrane Anatomy 0.000 description 3
210000003800 pharynx Anatomy 0.000 description 3
210000000813 small intestine Anatomy 0.000 description 3
239000003765 sweetening agent Substances 0.000 description 3
206010000087 Abdominal pain upper Diseases 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical group [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
239000001856 Ethyl cellulose Substances 0.000 description 2
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
229910052784 alkaline earth metal Inorganic materials 0.000 description 2
235000013361 beverage Nutrition 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
239000002706 dry binder Substances 0.000 description 2
235000019325 ethyl cellulose Nutrition 0.000 description 2
229920001249 ethyl cellulose Polymers 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
235000019634 flavors Nutrition 0.000 description 2
235000013305 food Nutrition 0.000 description 2
210000004051 gastric juice Anatomy 0.000 description 2
210000001156 gastric mucosa Anatomy 0.000 description 2
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
239000001863 hydroxypropyl cellulose Substances 0.000 description 2
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
229920000609 methyl cellulose Polymers 0.000 description 2
235000010981 methylcellulose Nutrition 0.000 description 2
239000001923 methylcellulose Substances 0.000 description 2
210000004877 mucosa Anatomy 0.000 description 2
239000006187 pill Substances 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000007787 solid Substances 0.000 description 2
URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
238000005303 weighing Methods 0.000 description 2
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
239000004925 Acrylic resin Substances 0.000 description 1
229920000178 Acrylic resin Polymers 0.000 description 1
208000006386 Bone Resorption Diseases 0.000 description 1
208000020084 Bone disease Diseases 0.000 description 1
BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 description 1
235000019739 Dicalciumphosphate Nutrition 0.000 description 1
DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 description 1
239000001263 FEMA 3042 Substances 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
208000037147 Hypercalcaemia Diseases 0.000 description 1
MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 1
239000005913 Maltodextrin Substances 0.000 description 1
229920002774 Maltodextrin Polymers 0.000 description 1
208000010191 Osteitis Deformans Diseases 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
208000027868 Paget disease Diseases 0.000 description 1
LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical class OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
HDSBZMRLPLPFLQ-UHFFFAOYSA-N Propylene glycol alginate Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(C)C(C(=O)OCC(C)O)O1 HDSBZMRLPLPFLQ-UHFFFAOYSA-N 0.000 description 1
IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 description 1
DKJJVAGXPKPDRL-UHFFFAOYSA-N Tiludronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)SC1=CC=C(Cl)C=C1 DKJJVAGXPKPDRL-UHFFFAOYSA-N 0.000 description 1
DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
UGEPSJNLORCRBO-UHFFFAOYSA-N [3-(dimethylamino)-1-hydroxy-1-phosphonopropyl]phosphonic acid Chemical compound CN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O UGEPSJNLORCRBO-UHFFFAOYSA-N 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000003513 alkali Substances 0.000 description 1
150000001342 alkaline earth metals Chemical class 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229960004977 anhydrous lactose Drugs 0.000 description 1
235000019568 aromas Nutrition 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
229920001222 biopolymer Polymers 0.000 description 1
230000024279 bone resorption Effects 0.000 description 1
229960005069 calcium Drugs 0.000 description 1
229960003563 calcium carbonate Drugs 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
229910001424 calcium ion Inorganic materials 0.000 description 1
229960001714 calcium phosphate Drugs 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 description 1
229960002286 clodronic acid Drugs 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
235000013365 dairy product Nutrition 0.000 description 1
239000008380 degradant Substances 0.000 description 1
229940031954 dibutyl sebacate Drugs 0.000 description 1
229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
229940038472 dicalcium phosphate Drugs 0.000 description 1
230000001079 digestive effect Effects 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
238000007922 dissolution test Methods 0.000 description 1
210000001198 duodenum Anatomy 0.000 description 1
238000009505 enteric coating Methods 0.000 description 1
239000002702 enteric coating Substances 0.000 description 1
229940009626 etidronate Drugs 0.000 description 1
238000009472 formulation Methods 0.000 description 1
235000011389 fruit/vegetable juice Nutrition 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000011521 glass Substances 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
239000001087 glyceryl triacetate Substances 0.000 description 1
235000013773 glyceryl triacetate Nutrition 0.000 description 1
239000000017 hydrogel Substances 0.000 description 1
230000000148 hypercalcaemia Effects 0.000 description 1
208000030915 hypercalcemia disease Diseases 0.000 description 1
229940015872 ibandronate Drugs 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
208000014674 injury Diseases 0.000 description 1
239000004922 lacquer Substances 0.000 description 1
229960001375 lactose Drugs 0.000 description 1
229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
229940035034 maltodextrin Drugs 0.000 description 1
208000027202 mammary Paget disease Diseases 0.000 description 1
235000012054 meals Nutrition 0.000 description 1
229940058213 medronate Drugs 0.000 description 1
MBKDYNNUVRNNRF-UHFFFAOYSA-N medronic acid Chemical compound OP(O)(=O)CP(O)(O)=O MBKDYNNUVRNNRF-UHFFFAOYSA-N 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
239000008267 milk Substances 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
235000019426 modified starch Nutrition 0.000 description 1
PUUSSSIBPPTKTP-UHFFFAOYSA-N neridronic acid Chemical compound NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O PUUSSSIBPPTKTP-UHFFFAOYSA-N 0.000 description 1
229950010733 neridronic acid Drugs 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
229940071572 oxidronate Drugs 0.000 description 1
HJZKOAYDRQLPME-UHFFFAOYSA-N oxidronic acid Chemical compound OP(=O)(O)C(O)P(O)(O)=O HJZKOAYDRQLPME-UHFFFAOYSA-N 0.000 description 1
239000003973 paint Substances 0.000 description 1
235000021317 phosphate Nutrition 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
239000000049 pigment Substances 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
229940068965 polysorbates Drugs 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
235000010409 propane-1,2-diol alginate Nutrition 0.000 description 1
239000000770 propane-1,2-diol alginate Substances 0.000 description 1
235000013772 propylene glycol Nutrition 0.000 description 1
229940089617 risedronate Drugs 0.000 description 1
PAYGMRRPBHYIMA-UHFFFAOYSA-N sodium;trihydrate Chemical compound O.O.O.[Na] PAYGMRRPBHYIMA-UHFFFAOYSA-N 0.000 description 1
229960002920 sorbitol Drugs 0.000 description 1
238000003860 storage Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
229920002258 tannic acid Polymers 0.000 description 1
LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
229940033123 tannic acid Drugs 0.000 description 1
235000015523 tannic acid Nutrition 0.000 description 1
229940019375 tiludronate Drugs 0.000 description 1
239000004408 titanium dioxide Substances 0.000 description 1
230000007704 transition Effects 0.000 description 1
229960002622 triacetin Drugs 0.000 description 1
239000001069 triethyl citrate Substances 0.000 description 1
235000013769 triethyl citrate Nutrition 0.000 description 1
VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
210000002438 upper gastrointestinal tract Anatomy 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Physical Education & Sports Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

SI200300052A 2003-02-27 2003-02-27 Farmacevtska oblika z alendronsko kislino, njenimi solmi ali estri ter postopek za njeno pripravo SI21403A (sl)

Priority Applications (8)

Application Number	Priority Date	Filing Date	Title
SI200300052A SI21403A (sl)	2003-02-27	2003-02-27	Farmacevtska oblika z alendronsko kislino, njenimi solmi ali estri ter postopek za njeno pripravo
EP04714997A EP1599191B1 (de)	2003-02-27	2004-02-26	Pharmazeutische zusammensetzung von alendronsäure, salze und ester davon, und ein verfahren zu deren herstellung
PL377706A PL377706A1 (pl)	2003-02-27	2004-02-26	Kompozycja farmaceutyczna zawierająca kwas alendronowy, jego sole lub estry oraz sposób jej otrzymywania
EA200501221A EA009333B1 (ru)	2003-02-27	2004-02-26	Фармацевтическая композиция алендроновой кислоты, ее солей или сложных эфиров и способ ее получения
CA2517372A CA2517372C (en)	2003-02-27	2004-02-26	Pharmaceutical composition of alendronic acid, salts or esters thereof, and a process for its preparation
PCT/SI2004/000011 WO2004075828A2 (en)	2003-02-27	2004-02-26	Pharmaceutical composition of alendronic acid, salts or esters thereof, and a process for its preparation
AT04714997T ATE464884T1 (de)	2003-02-27	2004-02-26	Pharmazeutische zusammensetzung von alendronsäure,salze und ester davon, und ein verfahren zu deren herstellung
DE602004026689T DE602004026689D1 (de)	2003-02-27	2004-02-26	Pharmazeutische zusammensetzung von alendronsäure, salze und ester davon, und ein verfahren zu deren herstellung

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
SI200300052A SI21403A (sl)	2003-02-27	2003-02-27	Farmacevtska oblika z alendronsko kislino, njenimi solmi ali estri ter postopek za njeno pripravo

Publications (1)

Publication Number	Publication Date
SI21403A true SI21403A (sl)	2004-08-31

Family

ID=32906916

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SI200300052A SI21403A (sl)	2003-02-27	2003-02-27	Farmacevtska oblika z alendronsko kislino, njenimi solmi ali estri ter postopek za njeno pripravo

Country Status (8)

Country	Link
EP (1)	EP1599191B1 (de)
AT (1)	ATE464884T1 (de)
CA (1)	CA2517372C (de)
DE (1)	DE602004026689D1 (de)
EA (1)	EA009333B1 (de)
PL (1)	PL377706A1 (de)
SI (1)	SI21403A (de)
WO (1)	WO2004075828A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1781258A1 (de) *	2004-08-20	2007-05-09	Mepha AG	Formulierungen von biphosphonaten
WO2006054165A1 (en) *	2004-11-19	2006-05-26	Ranbaxy Laboratories Limited	Pharmaceutical compositions of alendronic acid and processes for their preparation
PE20070698A1 (es)	2005-11-14	2007-08-17	Teijin Pharma Ltd	Comprimido de disgregacion rapida intraoral que contiene hidrocloruro de ambroxol
US20080131467A1 (en) *	2006-11-30	2008-06-05	Dennis Nelson	Film-coated solid dosage form
WO2009018834A1 (en) *	2007-08-06	2009-02-12	Pharmathen S.A.	Pharmaceutical composition containing bisphosphonate and method for the preparation thereof
US8715729B2 (en)	2010-12-22	2014-05-06	Basf Se	Rapidly disintegrating, solid coated dosage form
EP2654735B1 (de) *	2010-12-22	2016-04-13	Basf Se	Schnell zerfallende feste zubereitung mit filmüberzug
CN116211818B (zh) *	2023-03-10	2024-04-09	菲洋生物科技(吉林)有限公司	一种含有阿仑膦酸钠的片剂及其制备方法
CN118001336B (zh) *	2024-02-06	2026-03-27	泰华天然生物制药有限公司	一种便通片辅料、便通片及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL121623A (en) *	1997-08-26	2000-06-29	Unipharm Ltd	Process for the preparation of solid oral dosage forms comprising alendronic acid
US6432448B1 (en) *	1999-02-08	2002-08-13	Fmc Corporation	Edible coating composition
AU1195001A (en) *	1999-10-11	2001-04-23	Monsanto Company	Tablets coated with locust bean gum, guar gum or carrageenan gum
US6476006B2 (en) *	2000-06-23	2002-11-05	Teva Pharmaceutical Industries, Ltd.	Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates

2003
- 2003-02-27 SI SI200300052A patent/SI21403A/sl not_active IP Right Cessation
2004
- 2004-02-26 AT AT04714997T patent/ATE464884T1/de not_active IP Right Cessation
- 2004-02-26 EP EP04714997A patent/EP1599191B1/de not_active Expired - Lifetime
- 2004-02-26 WO PCT/SI2004/000011 patent/WO2004075828A2/en not_active Ceased
- 2004-02-26 PL PL377706A patent/PL377706A1/pl not_active Application Discontinuation
- 2004-02-26 DE DE602004026689T patent/DE602004026689D1/de not_active Expired - Lifetime
- 2004-02-26 EA EA200501221A patent/EA009333B1/ru not_active IP Right Cessation
- 2004-02-26 CA CA2517372A patent/CA2517372C/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
WO2004075828A2 (en)	2004-09-10
CA2517372A1 (en)	2004-09-10
ATE464884T1 (de)	2010-05-15
PL377706A1 (pl)	2006-02-06
EA200501221A1 (ru)	2006-04-28
DE602004026689D1 (de)	2010-06-02
EP1599191A2 (de)	2005-11-30
EA009333B1 (ru)	2007-12-28
WO2004075828A3 (en)	2004-10-28
EP1599191B1 (de)	2010-04-21
CA2517372C (en)	2012-07-17

Legal Events

Date	Code	Title	Description
2005-01-10	IF	Valid on the event date
2013-04-30	KO00	Lapse of patent	Effective date: 20130307

Publication	Publication Date	Title
ES2921141T3 (es)	2022-08-18	Forma farmacéutica oral sólida entérica de un bisfosfonato que contiene un agente quelante
RU2381791C2 (ru)	2010-02-20	Лекарственные формы ризедроната
JP5037746B2 (ja)	2012-10-03	イバンドロネートを含む経口薬理製剤
US20050026871A1 (en)	2005-02-03	Method of increasing bioavailability of alendronate or other bis-phosphonate by predose administration of vitamin D derivative
US20030158154A1 (en)	2003-08-21	Dosage forms for immediate gastric release of a calcium transport stimulator coupled with delayed gastric release of a bis-phosphonate
HUP0301400A2 (hu)	2003-09-29	Gyógyszerösszetétel és adagolási forma az alendronát és/vagy más biszfoszfonátoknak a gyomorban történż késleltetett felszabadulására
US10420725B2 (en)	2019-09-24	Solid dosage form of coated bisphosphonate particles
CN113490491A (zh)	2021-10-08	固体微粉化褪黑激素组合物
CA2517372C (en)	2012-07-17	Pharmaceutical composition of alendronic acid, salts or esters thereof, and a process for its preparation
EP1617826B1 (de)	2008-06-25	Dispergierbare alendronat-mikroteilchenformulierung
HK1150968B (en)	2022-07-29	Enteric solid oral dosage form of a bisphosphonate containing a chelating agent
HK1161130B (en)	2014-05-30	Enteric solid oral dosage form of bisphosphonate containing a chelating agent